Welcome to our dedicated page for Steris news (Ticker: STE), a resource for investors and traders seeking the latest updates and insights on Steris stock.
STERIS plc provides healthcare and life sciences products and services that support patient care, with an emphasis on infection prevention. Its recurring news includes financial results and outlook updates for continuing operations, quarterly dividend actions, conference-call announcements, and board or executive governance changes.
The company’s business updates center on sterilization services, Applied Sterilization Technologies, sterilizers, washer-disinfectors, and decontamination equipment and supplies used by care providers and biopharma manufacturing sites. Corporate announcements also address capital spending, cash flow expectations, and shareholder distribution information.
STERIS reported a 58% increase in second quarter revenue, reaching $1,197 million, compared to $756 million in Q2 fiscal 2021. The adjusted EPS rose to $1.99 from $1.48 year-over-year. The company indicated a strong recovery in procedure volumes, especially in the U.S., and reiterated its fiscal 2022 outlook for 10-11% organic revenue growth and adjusted EPS of $7.60 to $7.85. However, net income fell to $69.8 million, impacted by acquisition-related costs.
STERIS plc (NYSE: STE) announced a quarterly interim dividend of $0.43 per share, payable on December 17, 2021 to shareholders of record by November 23, 2021. The company emphasizes its role as a global provider focused on enhancing patient care through infection prevention. STERIS aims to create a healthier world with its innovative healthcare, life sciences, and dental products. For further details, visit www.steris.com.
STERIS plc (NYSE: STE) will host a conference call on November 3, 2021, at 10:00 a.m. ET to discuss its fiscal 2022 second quarter financial results. A press release detailing these results will be issued after the U.S. market closes on November 2, 2021. Investors can access the call live or via a replay on the STERIS investor relations website or by phone. STERIS provides innovative healthcare and infection prevention products and services, aiming to support patient care globally.
STERIS reported a strong fiscal 2022 Q1 with a 45% revenue increase to $968.4 million, compared to $668.9 million in Q1 of fiscal 2021. Adjusted net income was $159.9 million or $1.76 per diluted share, up from $113.3 million or $1.32 per diluted share year-over-year. The company increased its fiscal 2022 revenue outlook to approximately $4.6 billion and raised its dividend to $0.43 per share. The integration of Cantel Medical is on track, reflecting solid performance across Healthcare and Applied Sterilization Technologies.
STERIS plc (NYSE: STE) announced a conference call to discuss its fiscal 2022 first quarter financial results, scheduled for August 10, 2021, at 10:00 a.m. ET. Details of the financial results will be released after market close on August 9, 2021. Interested parties can participate via phone or online. STERIS aims to enhance healthcare and life science products globally, emphasizing a commitment to creating a safer world.
STERIS plc (NYSE: STE) has successfully completed the acquisition of Cantel Medical, enhancing its offerings in infection prevention across several sectors, including endoscopy and dental. The acquisition is expected to create more value for customers and shareholders, according to CEO Walt Rosebrough. Financial advisors included Guggenheim Securities for STERIS and Centerview Partners for Cantel. This strategic move aims to bolster STERIS's product range and global reach in the healthcare market, aligning with its mission to promote a healthier world.
STERIS plc reported 4Q21 revenue of $873.5 million, a 6% increase year-over-year, contributing to a 3% full-year growth to $3.1 billion. Diluted earnings per share (EPS) for 4Q21 was $1.02, down from $1.43 in 4Q20, while adjusted EPS remained steady at $1.63. For fiscal 2022, STERIS anticipates revenue around $4.5 billion and adjusted EPS between $7.40 - $7.65. The company also declared a dividend of $0.40 per share.
STERIS plc (NYSE: STE) announced the retirement of David B. Lewis from its Board effective July 29, 2021, after serving since 2010. Paul E. Martin, former CIO at Baxter International, has been appointed as a new Board member as of May 5, 2021. The Board will return to nine members post-Annual Meeting. CEO Walt Rosebrough will also not stand for re-election, with COO Dan Carestio expected to be appointed as new CEO. These transitions aim to enhance Board effectiveness and bring in valuable insights from experienced leaders.
STERIS plc (NYSE: STE) announced a conference call scheduled for May 19, 2021, at 11:00 a.m. ET to discuss its fiscal 2021 fourth quarter and full-year financial results. A press release detailing these financial results will follow on May 18, 2021, after U.S. market close. The call can be accessed via www.steris-ir.com or by phone. This event highlights STERIS's commitment to transparency with investors regarding its financial performance and future outlook.
STERIS expects to finalize the acquisition of Cantel Medical by June 2, 2021, pending a shareholder vote on April 29, 2021. For fiscal 2021, the company reported a revenue increase of approximately 3%, totaling $3.1 billion, and an anticipated income from operations of about $548 million. Additionally, adjusted income is projected at $699 million, with free cash flow around $447 million. The effective tax rate is expected between 19-20%. Comprehensive results will be shared in an earnings call on May 19, 2021.